Chemoinformaics analysis of Spirostan-3,6,23-triol, (3beta,5alpha,6alpha,23R,25S)-
| Molecular Weight | 448.644 | nRot | 0 |
| Heavy Atom Molecular Weight | 404.292 | nRig | 30 |
| Exact Molecular Weight | 448.319 | nRing | 6 |
| Solubility: LogS | -4.514 | nHRing | 2 |
| Solubility: LogP | 4.336 | No. of Aliphatic Rings | 6 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 4 |
| Atoms Count | 76 | No. of Aliphatic Hetero Cycles | 2 |
| No. of Heavy Atom | 32 | No. of Aromatic Carbocycles | 0 |
| nHetero | 5 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 4 |
| No. of Hydrogen atom | 44 | No. of Saturated Hetero Cycles | 2 |
| No. of Carbon atom | 27 | No. of Saturated Rings | 6 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 5 | No. of Arom Bond | 0 |
| nHA | 5 | APOL | 78.4389 |
| nHD | 3 | BPOL | 47.6131 |
| QED | 0.526 |
| Synth | 5.647 |
| Natural Product Likeliness | 3.222 |
| NR-PPAR-gamma | 0.398 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.996 |
| Pgp-sub | 0.999 |
| HIA | 0.014 |
| CACO-2 | -4.895 |
| MDCK | 0.0000372 |
| BBB | 0.289 |
| PPB | 0.506436 |
| VDSS | 0.983 |
| FU | 0.213172 |
| CYP1A2-inh | 0.027 |
| CYP1A2-sub | 0.699 |
| CYP2c19-inh | 0.009 |
| CYP2c19-sub | 0.629 |
| CYP2c9-inh | 0.021 |
| CYP2c9-sub | 0.017 |
| CYP2d6-inh | 0.002 |
| CYP2d6-sub | 0.102 |
| CYP3a4-inh | 0.185 |
| CYP3a4-sub | 0.174 |
| CL | 12.694 |
| T12 | 0.264 |
| hERG | 0.921 |
| Ames | 0.015 |
| ROA | 0.352 |
| SkinSen | 0.965 |
| Carcinogencity | 0.559 |
| EI | 0.173 |
| Respiratory | 0.971 |
| NR-Aromatase | 0.104 |
| Antiviral | Yes |
| Prediction | 0.753681 |